Alzamend Neuro (ALZN) Competitors $2.43 -0.03 (-1.22%) Closing price 04:00 PM EasternExtended Trading$2.44 +0.00 (+0.21%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALZN vs. PMN, AKTX, CVKD, DARE, ALLR, TENX, RNTX, MIRA, TRIB, and ASBPShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Promis Neurosciences (PMN), Akari Therapeutics (AKTX), Cadrenal Therapeutics (CVKD), Dare Bioscience (DARE), Allarity Therapeutics (ALLR), Tenax Therapeutics (TENX), Rein Therapeutics (RNTX), MIRA Pharmaceuticals (MIRA), Trinity Biotech (TRIB), and Aspire Biopharma (ASBP). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. Its Competitors Promis Neurosciences Akari Therapeutics Cadrenal Therapeutics Dare Bioscience Allarity Therapeutics Tenax Therapeutics Rein Therapeutics MIRA Pharmaceuticals Trinity Biotech Aspire Biopharma Promis Neurosciences (NASDAQ:PMN) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment. Which has more risk and volatility, PMN or ALZN? Promis Neurosciences has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.32, meaning that its stock price is 132% less volatile than the S&P 500. Does the media refer more to PMN or ALZN? In the previous week, Alzamend Neuro had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 2 mentions for Alzamend Neuro and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 1.87 beat Alzamend Neuro's score of 0.17 indicating that Promis Neurosciences is being referred to more favorably in the media. Company Overall Sentiment Promis Neurosciences Very Positive Alzamend Neuro Neutral Is PMN or ALZN more profitable? Alzamend Neuro's return on equity of -181.34% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Promis NeurosciencesN/A -266.69% -131.59% Alzamend Neuro N/A -181.34%-116.84% Do analysts rate PMN or ALZN? Promis Neurosciences presently has a consensus price target of $4.33, indicating a potential upside of 724.61%. Alzamend Neuro has a consensus price target of $45.00, indicating a potential upside of 1,751.85%. Given Alzamend Neuro's higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than Promis Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Promis Neurosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in PMN or ALZN? 50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 6.1% of Promis Neurosciences shares are owned by company insiders. Comparatively, 30.2% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, PMN or ALZN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPromis NeurosciencesN/AN/A$2.78M-$0.21-2.50Alzamend NeuroN/AN/A-$4.51MN/AN/A SummaryPromis Neurosciences and Alzamend Neuro tied by winning 5 of the 10 factors compared between the two stocks. Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.05M$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E RatioN/A21.2231.3126.60Price / SalesN/A390.30461.30121.37Price / CashN/A44.4437.7659.36Price / Book0.498.0710.026.67Net Income-$4.51M-$54.08M$3.27B$265.59M7 Day Performance3.40%2.26%3.17%3.42%1 Month Performance-12.27%3.42%4.34%1.09%1 Year Performance-88.61%18.61%44.11%23.85% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro2.8836 of 5 stars$2.43-1.2%$45.00+1,751.9%-89.2%$7.05MN/A0.004PMNPromis Neurosciences3.248 of 5 stars$0.54+1.8%$4.33+696.6%-59.3%$28.19MN/A-2.595Positive NewsAKTXAkari Therapeutics3.0643 of 5 stars$0.88-1.1%$5.00+471.4%-77.4%$28.16MN/A0.009Positive NewsCVKDCadrenal Therapeutics3.0952 of 5 stars$13.57+10.1%$32.00+135.8%+76.3%$27.82MN/A-1.534DAREDare Bioscience2.4929 of 5 stars$2.05-1.4%$12.00+485.4%-41.3%$27.77M$10K-0.9630ALLRAllarity Therapeutics2.9753 of 5 stars$1.88+100.0%$9.00+378.0%-67.9%$27.68MN/A0.0010News CoverageHigh Trading VolumeTENXTenax Therapeutics1.4817 of 5 stars$6.02+1.7%$17.00+182.4%+48.0%$27.45MN/A-6.549RNTXRein TherapeuticsN/A$1.16-1.7%N/AN/A$27.03MN/A-0.439Gap DownMIRAMIRA Pharmaceuticals3.0053 of 5 stars$1.41-1.1%$17.00+1,110.0%-30.1%$26.79MN/A-2.872TRIBTrinity Biotech1.3825 of 5 stars$1.48-4.8%N/A-88.2%$26.62M$61.56M-0.50480Upcoming EarningsGap UpASBPAspire BiopharmaN/A$0.53-4.2%N/AN/A$26.08MN/A0.00N/APositive News Related Companies and Tools Related Companies Promis Neurosciences Competitors Akari Therapeutics Competitors Cadrenal Therapeutics Competitors Dare Bioscience Competitors Allarity Therapeutics Competitors Tenax Therapeutics Competitors Rein Therapeutics Competitors MIRA Pharmaceuticals Competitors Trinity Biotech Competitors Aspire Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALZN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access